Enteral and Parenteral Treatment with Caffeine for Preterm Infants in the Delivery Room: A Randomised Trial

Background Early treatment with caffeine in the delivery room (DR) has been proposed to decrease the need for mechanical ventilation (MV) by limiting episodes of apnoea and improving respiratory mechanics in preterm infants. Our aim was to verify the hypothesis that intravenous or enteral administration of caffeine can be performed in the preterm infant in the DR. Methods Infants with 25(+/- 0)-29(+/- 6) weeks of gestational age were enrolled and randomised to receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth. Caffeine blood level was measured at 60 +/- 15 min after administration and 60 +/- 15 min before the next dose (5 mg/kg). The primary endpoint was evaluation of the success rate of intravenous and enteral administration of caffeine in the DR. Results Nineteen patients were treated with intravenous caffeine and 19 with enteral caffeine. In all patients the procedure was successfully performed. Peak blood level of caffeine 60 +/- 15 min after administration in the DR was found to be below the therapeutic range (5 mu g/mL) in 25 % of samples and above the therapeutic range in 3%. Blood level of caffeine 60 +/- 15 min before administration of the second dose was found to be below the therapeutic range in 18% of samples. Conclusions Intravenous and enteral administration of caffeine can be performed in the DR without interfering with infants' postnatal assistance. Some patients did not reach the therapeutic range, raising the question of which dose is the most effective to prevent MV.

Automated summary

This study aimed to verify the feasibility of intravenous or enteral administration of caffeine in the delivery room for preterm infants. The results showed that the procedure was successfully performed in all patients, but some patients did not reach the therapeutic range.